Logo image of ELDN

ELEDON PHARMACEUTICALS INC (ELDN) Stock Price, Quote, News and Overview

NASDAQ:ELDN - Nasdaq - US28617K1016 - Common Stock - Currency: USD

3.31  +0.03 (+0.91%)

After market: 3.31 0 (0%)

ELDN Quote, Performance and Key Statistics

ELEDON PHARMACEUTICALS INC

NASDAQ:ELDN (5/2/2025, 8:00:01 PM)

After market: 3.31 0 (0%)

3.31

+0.03 (+0.91%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High5.54
52 Week Low2
Market Cap198.20M
Shares59.88M
Float57.86M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)05-08 2025-05-08
IPO09-17 2014-09-17


ELDN short term performance overview.The bars show the price performance of ELDN in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 -10 -20 -30

ELDN long term performance overview.The bars show the price performance of ELDN in the last 1, 2 and 3 years. 1 year 2 years 3 years 10 20 30 40 50

The current stock price of ELDN is 3.31 USD. In the past month the price increased by 4.75%. In the past year, price increased by 37.34%.

ELEDON PHARMACEUTICALS INC / ELDN Daily stock chart

ELDN Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.33 351.09B
AMGN AMGEN INC 13.55 151.20B
GILD GILEAD SCIENCES INC 13.4 129.08B
VRTX VERTEX PHARMACEUTICALS INC 1728.1 128.84B
REGN REGENERON PHARMACEUTICALS 13.67 65.39B
ARGX ARGENX SE - ADR 341.93 39.67B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 33.74B
ONC BEIGENE LTD-ADR N/A 27.57B
BNTX BIONTECH SE-ADR N/A 25.23B
NTRA NATERA INC N/A 21.30B
SMMT SUMMIT THERAPEUTICS INC N/A 20.72B
BIIB BIOGEN INC 7.81 18.10B

About ELDN

Company Profile

ELDN logo image Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people requiring an organ or cellular transplant, and for people living with autoimmune and neurodegenerative disease. The company is headquartered in Irvine, California and currently employs 31 full-time employees. The company went IPO on 2014-09-17. The firm is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target within the costimulatory CD40/CD40L cellular pathway. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. Tegoprubart is engineered to potentially both improve safety and provides pharmacokinetic, pharmacodynamic, and dosing advantages. CD40L is primarily expressed on activated CD4+ T cells, platelets, and endothelial cells while the CD40 receptor is constitutively expressed on antigen-presenting cells, such as macrophages and dendritic cells, as well as B cells.

Company Info

ELEDON PHARMACEUTICALS INC

19800 Macarthur Blvd., Suite 250

Irvine CALIFORNIA 92612 US

CEO: David-Alexandre C. Gros

Employees: 20

ELDN Company Website

ELDN Investor Relations

Phone: 19492388090

ELEDON PHARMACEUTICALS INC / ELDN FAQ

What is the stock price of ELEDON PHARMACEUTICALS INC today?

The current stock price of ELDN is 3.31 USD. The price increased by 0.91% in the last trading session.


What is the ticker symbol for ELEDON PHARMACEUTICALS INC stock?

The exchange symbol of ELEDON PHARMACEUTICALS INC is ELDN and it is listed on the Nasdaq exchange.


On which exchange is ELDN stock listed?

ELDN stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for ELEDON PHARMACEUTICALS INC stock?

12 analysts have analysed ELDN and the average price target is 10.61 USD. This implies a price increase of 220.48% is expected in the next year compared to the current price of 3.31. Check the ELEDON PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is ELEDON PHARMACEUTICALS INC worth?

ELEDON PHARMACEUTICALS INC (ELDN) has a market capitalization of 198.20M USD. This makes ELDN a Micro Cap stock.


How many employees does ELEDON PHARMACEUTICALS INC have?

ELEDON PHARMACEUTICALS INC (ELDN) currently has 20 employees.


What are the support and resistance levels for ELEDON PHARMACEUTICALS INC (ELDN) stock?

ELEDON PHARMACEUTICALS INC (ELDN) has a support level at 3.15 and a resistance level at 3.39. Check the full technical report for a detailed analysis of ELDN support and resistance levels.


Should I buy ELEDON PHARMACEUTICALS INC (ELDN) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does ELEDON PHARMACEUTICALS INC (ELDN) stock pay dividends?

ELDN does not pay a dividend.


When does ELEDON PHARMACEUTICALS INC (ELDN) report earnings?

ELEDON PHARMACEUTICALS INC (ELDN) will report earnings on 2025-05-08.


What is the Price/Earnings (PE) ratio of ELEDON PHARMACEUTICALS INC (ELDN)?

ELEDON PHARMACEUTICALS INC (ELDN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.05).


What is the Short Interest ratio of ELEDON PHARMACEUTICALS INC (ELDN) stock?

The outstanding short interest for ELEDON PHARMACEUTICALS INC (ELDN) is 3.03% of its float. Check the ownership tab for more information on the ELDN short interest.


ELDN Technical Analysis

ChartMill assigns a technical rating of 2 / 10 to ELDN. When comparing the yearly performance of all stocks, ELDN is one of the better performing stocks in the market, outperforming 76.19% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

ELDN Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to ELDN. ELDN has a great financial health rating, but its profitability evaluates not so good.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ELDN Financial Highlights

Over the last trailing twelve months ELDN reported a non-GAAP Earnings per Share(EPS) of -1.05. The EPS increased by 41.34% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -33.72%
ROE -50.63%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%331.03%
Sales Q2Q%N/A
EPS 1Y (TTM)41.34%
Revenue 1Y (TTM)N/A

ELDN Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 85% to ELDN. The Buy consensus is the average rating of analysts ratings from 12 analysts.


Ownership
Inst Owners59.15%
Ins Owners0.03%
Short Float %3.03%
Short Ratio7.77
Analysts
Analysts85
Price Target10.61 (220.54%)
EPS Next Y-15.36%
Revenue Next YearN/A